Core Insights - The report from CMB International indicates a leading rating for the mainland pharmaceutical industry, following the National Healthcare Security Administration's announcement of the results from the 2025 Innovative Drug High-Quality Development Conference [1] Group 1: Industry Developments - The recent negotiations for the medical insurance and commercial insurance innovative drug catalog have resulted in many innovative pharmaceutical companies covered by CMB International having products newly included or successfully renewed in the insurance coverage [1] - Companies such as Heng Rui Medicine (600276), Innovent Biologics (01801), CanSino Biologics (09926), and China National Pharmaceutical Group (01177) have more than five products that received new coverage or new indications [1] Group 2: Market Outlook - The inclusion of more new drugs in the catalog is expected to enhance clinical medication levels and improve the overall R&D return rates in the innovative drug industry [1] - The introduction of commercial insurance funds is anticipated to provide significant incremental funding for innovative drug payments, paving the way for a diversified payment system alongside basic medical insurance [1] Group 3: Future Growth Potential - CMB International is optimistic about the sales growth potential of newly included products/indications in 2026, particularly for potential blockbuster products from companies like CanSino Biologics [1] - The report emphasizes the importance of monitoring the actual execution and payment situations of the first batch of commercial insurance catalog, as well as the dynamic adjustments in the list and pricing, and the long-term development opportunities arising from real-world data accumulation [1]

Group 1 - Morgan Stanley reported that the stock price of Innovent Biologics (01801.HK) fell by approximately 7% on Monday, which may be related to the recently announced National Reimbursement Drug List (NRDL) [1] - The investment bank maintains an "Overweight" rating on the stock, with nearly 12 investment firms issuing buy ratings in the past 90 days, and the average target price over this period is HKD 118.29 [1] - CITIC Securities recently provided a buy rating for Innovent Biologics with a target price of HKD 136.12 [1] Group 2 - Innovent Biologics has a market capitalization of HKD 147.301 billion and ranks second in the biopharmaceutical II industry [2]

Core Viewpoint - Morgan Stanley reports that the stock price of Innovent Biologics (01801) fell approximately 7% on Monday, likely due to the recently announced National Reimbursement Drug List (NRDL) [1] Group 1: Investor Concerns - Investors are concerned that Eli Lilly's (LLY.US) tirzepatide being included in the NRDL for diabetes treatment may pressure the sales potential of Innovent's mazdutide [1] - There are worries that Innovent may need to significantly reduce the prices of its small molecule inhibitors to gain NRDL coverage, which could exacerbate sales pressure [1] Group 2: Drug Development Insights - Morgan Stanley finds the preliminary data for Innovent's trispecific antibody drug IBI3003, to be presented at ASH'25, encouraging, suggesting its efficacy may be comparable to Johnson & Johnson's (JNJ.US) trispecific antibody drug JNJ-5322 [1]

Core Viewpoint - Morgan Stanley reports that the stock price of Innovent Biologics (01801) fell approximately 7% on Monday, likely due to the recently announced National Reimbursement Drug List (NRDL) [1] Group 1: Investor Concerns - Investors are concerned that Eli Lilly's (LLY.US) tirzepatide being included in the NRDL for diabetes treatment may pressure the sales potential of Innovent's mazdutide [1] - There are worries that Innovent may significantly reduce the prices of its small molecule inhibitors to gain NRDL coverage, which could exacerbate sales pressure [1] Group 2: Drug Development Insights - Morgan Stanley notes that the preliminary data for Innovent's trispecific antibody drug IBI3003, to be presented at ASH'25, is encouraging and its efficacy may be comparable to Johnson & Johnson's (JNJ.US) trispecific antibody drug JNJ-5322 [1]

Investment Rating - The report maintains a "Positive" investment rating for the pharmaceutical and biotechnology industry, indicating an expected return that is stronger than the market benchmark by over 5% [5]. Core Insights - The National Medical Insurance Administration is strongly encouraging the high-quality development of innovative drugs, with clear policies supporting the payment side for innovative drugs. Domestic leading innovative drug companies are entering a commercial realization phase [3][7]. - The 2025 National Medical Insurance Drug List includes 127 products, with 114 successfully added, of which 50 are innovative drugs, marking a historical high. The overall negotiation success rate reached 90%, the highest in nearly seven years [7]. - The report highlights that the domestic innovative drug market is becoming increasingly concentrated, with leading companies like Heng Rui and Xin Da Biotech significantly benefiting from the new insurance policies [7]. Summary by Sections Investment Recommendations and Targets - Recommended stocks include Heng Rui Pharmaceutical (600276, Buy), Ke Lun Pharmaceutical (002422, Buy), Xin Li Tai (002294, Hold), Ao Sai Kang (002755, Buy), Jing Xin Pharmaceutical (002020, Buy), and others [3]. Market Dynamics - The report notes that the introduction of the commercial insurance directory marks the beginning of a "new golden decade" for Chinese innovative drugs, with a focus on high clinical efficacy and value innovation [7]. - The report emphasizes that the competition in the GLP-1 market remains clear, with the entry of new drugs not significantly altering the competitive landscape for existing treatments [7].

Core Insights - Innovent Biologics has successfully dosed the first participant in a Phase 1 clinical trial of IBI3011, an anti-IL-1RAP monoclonal antibody aimed at treating gout flares [1][7] Clinical Development - The Phase 1 trial is a single ascending dose study designed to evaluate the safety, tolerability, and pharmacokinetics of IBI3011, with plans to enroll 40 healthy volunteers and 24 patients with gout flares [2] - IBI3011 is the first anti-IL1RAP monoclonal antibody in China, showing significant potential in preclinical models for suppressing gout flares [6][9] Market Need - The number of gout patients in China has exceeded 3 million as of 2019, with rising living standards contributing to this increase [3] - Current treatments for gout flares are limited, with only one IL-1 targeted agent approved in China, indicating a substantial unmet clinical need [4] Mechanism of Action - IL-1RAP acts as a co-receptor that mediates inflammatory signaling pathways, and targeting it can block multiple IL-1 family pathways, potentially leading to rapid control of inflammation and alleviation of gout symptoms [5][9] Future Prospects - Innovent plans to initiate a Phase 3 trial of IBI128 (tigulixostat) for gout patients with hyperuricemia, which has shown strong efficacy in reducing serum uric acid levels in Phase 2 trials [6][7] - The combination of IBI3011 and IBI128 is expected to provide a comprehensive treatment approach for patients with gout and hyperuricemia, enhancing personalized treatment options [6][7] Company Overview - Innovent Biologics, founded in 2011, focuses on developing high-quality biopharmaceuticals for various diseases, having launched 17 products and currently having multiple assets in clinical trials [10] - The company collaborates with over 30 global healthcare companies, enhancing its research and development capabilities [10]

Core Insights - On December 9, 2025, Alibaba-W (09988), Xiaomi Group-W (01810), and Tencent Holdings (00700) were the top three companies by trading volume in the southbound trading of the Stock Connect, with trading amounts of 4.115 billion, 3.321 billion, and 2.930 billion respectively [1] - In the Shenzhen-Hong Kong Stock Connect, Alibaba-W (09988), Tencent Holdings (00700), and SMIC (00981) led the trading volume, with amounts of 3.237 billion, 1.987 billion, and 1.503 billion respectively [1] Southbound Trading Highlights - **Top Active Companies in Southbound Trading (Shanghai-Hong Kong Stock Connect)** - Alibaba-W (09988): Trading amount of 4.115 billion, net inflow of 83.45 million [2] - Xiaomi Group-W (01810): Trading amount of 3.321 billion, net inflow of 156 million [2] - Tencent Holdings (00700): Trading amount of 2.930 billion, net inflow of 1.126 billion [2] - SMIC (00981): Trading amount of 2.806 billion, net outflow of 133 million [2] - Pop Mart (09992): Trading amount of 1.880 billion, net outflow of 438 million [2] - **Top Active Companies in Southbound Trading (Shenzhen-Hong Kong Stock Connect)** - Alibaba-W (09988): Trading amount of 3.237 billion, net inflow of 342 million [2] - Tencent Holdings (00700): Trading amount of 1.987 billion, net outflow of 248 million [2] - SMIC (00981): Trading amount of 1.503 billion, net inflow of 14.69 million [2] - Xiaomi Group-W (01810): Trading amount of 1.203 billion, net inflow of 384 million [2] - Pop Mart (09992): Trading amount of 1.016 billion, net outflow of 136 million [2]

Core Insights - The Hong Kong stock market saw a net inflow of 531 million HKD from Northbound trading on December 9, with a net sell of 352 million HKD through the Shanghai Stock Connect and a net buy of 883 million HKD through the Shenzhen Stock Connect [1] Group 1: Stock Performance - Tencent (00700) received a net buy of 877 million HKD, while Alibaba (09988) had a net buy of 425 million HKD [5] - Xiaomi Group (01810) experienced a net buy of 539 million HKD [5] - Agricultural Bank (01288) saw a net buy of 306 million HKD, whereas China Construction Bank (00939) faced a net sell of 47.47 million HKD [6] - Huahong Semiconductor (01347) had a net buy of 250 million HKD, while SMIC (00981) experienced a net sell of 118 million HKD [6] - Innovent Biologics (01801) received a net buy of 179 million HKD [6] - Three Biopharmaceuticals (01530) faced a net sell of 91.39 million HKD due to a planned share placement [7] Group 2: Market Trends and Predictions - Analysts predict that AI integration will accelerate, benefiting Tencent through AI advertising and gaming, with expected revenue growth exceeding 10% and profit growth over 16% by fiscal year 2026 [5] - Xiaomi is expected to announce more AI developments that will enhance its ecosystem and support its "people, vehicle, home" strategy [5] - The banking sector is expected to see improved valuations as the negative impact of asset risks on financial indicators diminishes [6] - The U.S. will allow NVIDIA to sell AI chips to approved Chinese customers, which may influence the semiconductor market dynamics [6]

Core Viewpoint - Morgan Stanley's report indicates that the inclusion of Eli Lilly's Tirzepatide in the national medical insurance directory was not entirely unexpected, and they believe that Innovent Biologics (01801) can adopt flexible pricing strategies for its Mazdutide product [1] Group 1: Market Potential - The Chinese weight loss drug market is vast, with sufficient space for the development of multiple blockbuster drugs [1] - Morgan Stanley predicts that by 2027, Innovent will have over ten products on the market, with sales potentially reaching 17 billion RMB [1] Group 2: Company Outlook - Innovent Biologics is rated "Overweight" by Morgan Stanley, with a positive outlook on its product pipeline, which includes areas such as oncology, autoimmune diseases, metabolic diseases, and ophthalmology [1] - Investors may focus on the company's ability to license assets externally in the short to medium term [1] Group 3: Stock Performance - On October 8, Innovent's stock price fell by approximately 7%, compared to a 1.5% decline in the Hang Seng Healthcare Index (HSHCI) on the same day [1] - Concerns among investors include the potential impact of Eli Lilly's Tirzepatide on the sales potential of Innovent's Mazdutide, as well as worries about possible excessive price reductions to include small molecule inhibitors in the insurance directory [1]

Core Viewpoint - Morgan Stanley expresses that the inclusion of Eli Lilly's Tirzepatide in the national medical insurance directory is not entirely surprising and believes that Innovent Biologics (01801) can adopt flexible pricing strategies to respond to market changes [1] Group 1: Market Potential and Product Pipeline - The Chinese weight loss drug market is vast, providing ample space for the development of multiple blockbuster drugs [1] - Innovent Biologics is rated "Overweight" due to its product pipeline covering various fields including oncology, autoimmune diseases, metabolic diseases, and ophthalmology [1] - Short to medium-term investors may focus on the company's ability to license assets externally [1] Group 2: Sales Forecast and Target Price - Morgan Stanley predicts that by 2027, Innovent will have over ten products on the market, with sales potentially reaching 17 billion RMB [1] - A target price of 110 HKD is set for Innovent Biologics [1] Group 3: Stock Performance and Investor Sentiment - On October 8, Innovent Biologics' stock price fell by approximately 7%, compared to a 1.5% decline in the Hang Seng Healthcare Index (HSHCI) on the same day [1] - Investor concerns are linked to the recent announcement regarding the national medical insurance drug directory negotiations, particularly regarding the impact of Eli Lilly's Tirzepatide on the sales potential of Innovent's Mazdutide [1] - There are also worries that Innovent may need to implement greater-than-expected price reductions to include small molecule inhibitors in the medical insurance directory [1]